Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types.

Author information

Affiliations

  • 1. Dept of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden Both authors contributed equally.
      Authors
    • Browall S 1
    (1 author)
  • 2. Dept of Infectious Diseases, Skaraborg Hospital, Skövde, Sweden Both authors contributed equally.
      Authors
    • Backhaus E 2
    (1 author)
  • 3. Dept of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden Dept of Infectious Diseases, Karolinska University Hospital, Solna, Sweden.
      Authors
    • Naucler P 3
    (1 author)
  • 4. Dept of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
      Authors
    • Galanis I 4
    • Sjöström K 4
    (2 authors)
  • 5. Systems Biology Research Centre, School of Biosciences, University of Skövde, Skövde, Sweden.
      Authors
    • Karlsson D 5
    • Ejdebäck M 5
    (2 authors)
    • Show all (12)

ORCIDs linked to this article

The European Respiratory Journal, 16 Oct 2014, 44(6):1646-1657
https://doi.org/10.1183/09031936.00080814 PMID: 25323223 

Abstract 

Pneumococcal conjugated vaccines (PCVs) have shown protection against invasive pneumococcal disease by vaccine serotypes, but an increase in non-vaccine serotype disease has been observed. Type-specific effects on clinical manifestation need to be explored. Clinical data from 2096 adults and 192 children with invasive pneumococcal disease were correlated to pneumococcal molecular serotypes. Invasive disease potential for pneumococcal serotypes were calculated using 165 invasive and 550 carriage isolates from children. The invasive disease potential was lower for non-PCV13 compared to vaccine-type strains. Patients infected with non-PCV13 strains had more underlying diseases, were less likely to have pneumonia and, in adults, tended to have a higher mortality. Furthermore, patients infected with pneumococci belonging to clonal serotypes only expressing non-PCV13 capsules had a higher risk for septicaemia and mortality. PCV vaccination will probably lead to a decrease in invasive pneumococcal disease but an alteration in the clinical manifestation of invasive pneumococcal disease. Genetic lineages causing invasive pneumococcal disease in adults often express non-vaccine serotypes, which can expand after vaccination with an increased risk of infection in patients with underlying diseases.

Full text links 

Read article at publisher's site: https://doi.org/10.1183/09031936.00080814

Read article for free, from open access legal sources, via Unpaywall: https://erj.ersjournals.com/content/erj/44/6/1646.full.pdfUnpaywall

References 

Articles referenced by this article (32)

Show 10 more references (10 of 32)

Citations & impact 

Impact metrics

26
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2990025
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2990025

Article citations

Go to all (26) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.